Rankings
▼
Calendar
CCCC Q2 2023 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CCCC
C4 Therapeutics, Inc.
$243M
Q2 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
-80.7% YoY
Gross Profit
$3M
100.0% margin
Operating Income
-$38M
-1410.2% margin
Net Income
-$36M
-1348.4% margin
EPS (Diluted)
$-0.73
QoQ Revenue Growth
-29.1%
Cash Flow
Operating Cash Flow
-$19M
Free Cash Flow
-$19M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$375M
Total Liabilities
$141M
Stockholders' Equity
$234M
Cash & Equivalents
$45M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$14M
-80.7%
Gross Profit
$3M
-$17M
+115.2%
Operating Income
-$38M
-$27M
-37.2%
Net Income
-$36M
-$27M
-31.0%
← FY 2023
All Quarters
Q3 2023 →